hotspot -WSS

hotspot

author：knowledge 2025-09-03 09:24:16 - browse：98596

The FDA building -- First Opinion coverage from STAT — Adobe

A panel of independent advisers to the Food and Drug Administration voted overwhelmingly against a polarizing potential treatment for ALS on Wednesday, concluding that the medicine’s messy supporting data did not meet the standard for approval.

After a day-long meeting that included impassioned testimony from ALS patients, the agency’s expert advisers voted 17-1 with one abstention that the case for NurOwn, a treatment from BrainStorm Cell Therapeutics, was based too heavily on convoluted clinical trial results and compelling but unreliable anecdotal evidence.

“Patients and families need hope, but providing false hope can be ethically problematic,” said panelist Lisa Lee, a bioethicist at Virginia Tech. “False hope is provided when the probability of a positive outcome is overestimated, and I think that seems to be the case here.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： How Long Island became the ‘eugenics capital of the world’

entertainment

WSS

As Taiwan prepares for anti

New rules on organ donation and transplantation 'will bring chaos'

In science, is the line between industry and academia shifting?

Feds fine Medicare Advantage plans for overcharging members

Medicare explains how it will choose drugs for negotiation

2024 GOP presidential candidates spar over abortion in debate

hotspot

hotspot

Wikipedia

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Medicare explains how it will choose drugs for negotiation

How to save PrEP access — and even expand it

A double vaccine crisis is endangering millions of children

DIEP, the 'gold standard' of breast reconstruction, is under threat

Medicare explains how it will choose drugs for negotiation

As demand for Covid shots wanes, Moderna seeks its next success

How artificial intelligence is being used to detect, treat cancer

Alkermes shareholders re

AstraZeneca challenges Medicare drug negotiation program

focus

FDA official pushes for dedicated emerging pathogens team

Artificial intelligence advances fuel industry trying to preserve loved ones after death

Providers still hesitate to prescribe buprenorphine, study finds

Radiation, mainstay of cancer treatment, begins a fade

Winners, losers from Medicare’s list of drugs subject to price talks

What AAP's gender

entertainment

hotspot

entertainment

hotspot